Drugs / TAS0728
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03410927 | Apr 2018 → Jun 2022 | — | Taiho Oncology, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS0728 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03410927 ↗ |
| Action | Inhibit | “Here, we report a novel compound TAS0728 that covalently binds to HER2 at C805 and selectively inhibits its kinase activity.” PMID 30787176 ↗ Feb 2019 |
| Modality | Small molecule | “Here, we report a novel compound TAS0728 that covalently binds to HER2 at C805 and selectively inhibits its kinase activity.” PMID 30787176 ↗ Feb 2019 |
| Route | Oral | “It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT.” NCT03410927 ↗ |
| Target | ERBB2 | “TAS0728 is an oral covalent binding inhibitor of human epidermal growth factor receptor 2 (HER2).” PMID 33774767 ↗ Mar 2021 |